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Introduction
Use of molecular imaging biomarkers such as amyloid-b PET significantly improves the clinical diagnosis of Alzheimer's dementia (McKhann et al., 2011; Barthel et al., 2015) . However, amyloid-b PET is insufficient as surrogate marker for the prediction of neurodegenerative progression and cognitive deterioration. This is because a substantial number of elderly, apparently healthy subjects with significant amyloid-b plaque load do not develop frank dementia (Aizenstein et al., 2008; Rowe et al., 2010) . Thus, there is a need for PET biomarkers of disease progression with close associations to cognitive dysfunction that may aid to predict further cognitive decline and neurodegeneration in mild Alzheimer's dementia (Teipel et al., 2013) .
According to the cholinergic hypothesis, there are deficiencies in the cholinergic pathways in Alzheimer's dementia which are associated with cognitive impairment (Francis et al., 1999) . In experimental Alzheimer's dementia, low levels of soluble amyloid-b inhibit cholinergic synaptic function even before significant amyloid-plaque loads occur (Klingner et al., 2003; Lesné et al., 2006; Schliebs and Arendt, 2011) . The a4b2 nicotinic acetylcholine receptors (a4b2-AChRs) are widely expressed in the human brain, and decisively involved in cognitive functions such as attention, learning, and memory (Dani and Bertrand, 2007; Nees, 2015) . Thus, PET imaging of cerebral a4b2-nAChRs might be sensitive to detect abnormalities early in the course of Alzheimer's dementia. In support of this assumption, post-mortem studies in patients with Alzheimer's dementia identified substantial decline in a4b2-nAChRs (Rinne et al., 1991; Perry et al., 1995) . High-affinity a4b2-nAChR PET radioligands, such as 2- 18 F-F-A85380, were developed to quantify a4b2-nAChR availability in the human brain in vivo (Kimes et al., 2003) . PET investigations in patients with Alzheimer's dementia and amnestic mild cognitive impairment, later converting to Alzheimer's dementia suggest that reductions of a4b2-nAChR availability are present early in the course of the disease and associated with cognitive dysfunction (Sabri et al., 2008; Kendziorra et al., 2011; Okada et al., 2013) . In contrast, other PET/SPECT studies did not find any significant differences of a4b2-nAChR availability between mild Alzheimer's dementia and healthy controls or relationships to cognitive dysfunction (Ellis et al., 2008; Mitsis et al., 2009b) . This has led to the ongoing controversy regarding the questions, whether there is a decrease of a4b2-nAChR availability in mild Alzheimer's dementia and whether this decrease is related to cognitive decline. The relatively slow kinetics of 2-18 F-F-A85380 requiring acquisition times up to 7 h for full kinetic modelling, limits its use for clinical applications (Sabri et al., 2008) . Recently, a new generation of a4b2-nAChR-specific PET radioligands, such as (À)- 18 F-flubatine, or 18 F-AZAN and 18 F-nifene, has been developed, showing high specific binding combined with fast kinetics (Brust et al., 2008; Hillmer et al., 2011; Wong et al., 2013) . We have previously published the pharmacokinetic modelling results of (À)- 18 F-flubatine PET in healthy male subjects and identified favourable characteristics, i.e. (i) high brain uptake; (ii) fast kinetics; (iii) high stability; (iv) ability to describe a4b2-nAChR binding by a simple one-tissuecompartment model within 90 min for all regions of interest; and (v) proven safety and tolerability (Sattler et al., 2014; Sabri et al., 2015) . In the current PET study, (À)- 18 F-Flubatine has been applied in patients with Alzheimer's dementia in order to quantify alterations of a4b2-nAChRs. We hypothesize that (i) in mild Alzheimer's dementia compared with healthy controls, a4b2-nAChR availability is lower in distinct areas of the brain, especially those involving the fronto-temporo-parietal cortices and basal forebrain; and (ii) in Alzheimer's dementia, there is a relationship between a4b2-nAChR availability and domainspecific cognitive performance.
Materials and methods
This is a proof-of-concept, first-in-human study of prospectively recruited patients with Alzheimer's dementia and healthy, elderly controls, using the recently developed radioligand (À)- 18 F-flubatine to investigate the a4b2-nAChR availability. In the previously published first part of this PET study, the kinetic modelling characteristics of (À)- 18 F-flubatine have been described (Sabri et al., 2015) .
Cohorts
Fourteen patients with mean (range) age 75.1 (58-83) years, with mild Alzheimer's dementia from the Department of Psychiatry, University Hospital Leipzig were compared with 15 healthy control subjects with mean (range) age 71.3 (63-77) years. To avoid possible effects not related to disease pathophysiology, patients with Alzheimer's dementia and healthy controls were matched for age, sex and education (Meyer et al., 2009; Mitsis et al., 2009a; Garibotto et al., 2013) . To achieve this patients and healthy controls were derived from a larger, unmatched study population (n = 41). All study subjects were non-smokers, drug-naïve for cholinesterase inhibitors, drug-free for any kind of centrally acting medication and had no history of neurological or psychiatric disorder other than Alzheimer's dementia. The diagnosis of mild, probable Alzheimer's dementia was made according to the NINCDS-ADRDA criteria characterized by progressive cognitive decline (in accordance with DSM-IV criteria for dementia), and a score of 1 on the Clinical Dementia Rating scale (CDR) and 24.0 AE 2.6 mean AE standard deviation (SD) on the Mini-Mental State Examination (MMSE). Healthy controls (CDR = 0) were recruited by newspaper advertisement and were required to achieve psychometric test results within 1 SD of the mean of reference normative data as provided by standard test manuals.
All subjects and patients gave written informed consent. The study was performed according to the 1964 Declaration of Helsinki and subsequent revisions, and was approved by the local ethics committee and the other competent authorities in Germany.
Neuropsychological assessment
This neuropsychological assessment included the full CERADPlus test battery (Category fluency, Letter fluency, Boston Naming Test, MMSE, Wordlist immediate and delayed recall; Wordlist savings score; Trail Making Test A and B), the subtests Logical Memory and Digit Span from the revised Wechsler Memory Scale, the Alters-Konzentrations-Test (AKT-G; a standardized geriatric cancellation test measuring attention/concentration), the Clock Drawing Test, the MultipleChoice Vocabulary Intelligence Test (Morris et al., 1989; Sunderland et al., 1989; Hä rting et al., 2000; Lehrl, 2005; Gatterer, 2008) , and the Geriatric Depression Scale (GDS; Yesavage et al., 1982 Yesavage et al., -1983 . Raw scores were converted to Z-scores by means of the normative data provided in the corresponding test manuals. Z-scores of relevant subtests were averaged to calculate five cognitive domains of interest, that are attention (AKT-G, digit span forward); executive function/ working memory (Trail-Making-Test-B/A, letter fluency, digit span backward); visuospatial abilities (CERAD: visuoconstruction copy and recall), language (Boston Naming Test, category fluency); and episodic memory (CERAD: wordlist immediate and delayed recall, wordlist savings, visuoconstruction savings; WMS-R: Logical Memory immediate and delayed recall).
PET imaging procedures, kinetic modelling and analysis (À)-18 F-flubatine was synthesized according to a recently published fully automated and good manufacturing practice compliant procedure (Patt et al., 2013) . The specific activity of (À)-18 F-flubatine was $1500 GBq/mmol at the time of injection (Patt et al., 2013) . PET data were obtained in 3D scanning mode with an ECAT Exact HR + system [Siemens/CTI, 63 slices, resolution 4.7 mm full-width at half-maximum (FWHM)] after the injection 90 s continuous short infusion (10 ml solution) of a dose of $370 MBq (À)-18 F-flubatine. Emission measurements consisted of one dynamic PET scan of 90 min (23 frames) and three subsequent scans (30 min, six frames each) starting at 2, 3 and 4 h post-injection, resulting in a total acquisition time of 270 min. Between the PET scans, starting after the first 90 min, patients and healthy controls were allowed to leave the PET system. PET data were corrected for scatter, attenuation (as estimated by means of a 10-min transmission scan acquired with three rotating 68 Ge rod sources before the first emission scan), and radioactive decay, and reconstructed by ordered subset expectation maximization with 10 iterations and 16 subsets with a pixel size of 0.2574 Â 0.2574 Â 0.2425 cm. PET and blood data processing were performed as recently described in detail. In the current data analysis only 0 to 90 min dynamic data were used since kinetic data analysis has shown that analysis of 0 to 90 min dynamic data allows accurate quantification of all brain regions (Patt et al., 2014; Sabri et al., 2015) . In brief, tissue time activity curves from 0 to 90 min were used for kinetic analysis with a one-tissue compartment model to calculate the total distribution volume (V T ). For SPM analysis we needed a voxel-based approach to compute the distribution volume V T . Thus, Logan's graphical analysis was applied on a voxel-wise basis to compute parametric images of V T . Approximately 35 arterial plasma samples were obtained per subject to create individual input functions for kinetic modelling. Metabolite analysis showed high stability in vivo with 90% untransformed parent compound at 90 min. Because of the low number of metabolites (Sabri et al., 2015) and to avoid errors introduced by the metabolite correction, the results presented were computed without metabolite correction. As recently reported, the plasma protein binding was 15 AE 2% and did not differ significantly between patients with Alzheimer's dementia and healthy controls (Patt et al., 2014) . K 1 is the delivery rate constant and equals the product of blood flow and extraction fraction of the radiotracer. As the extraction fraction is high for this tracer (Sabri et al., 2015) , K 1 was used as brain blood flow surrogate and indirect measure of neurodegeneration. K 1 values were computed from the PET data within a composite volume of interest, comprising the frontal, temporal, and parietal cortices, regions typically affected in Alzheimer's dementia.
It could be possible that the specific binding portion of the distribution volume (V S )-not contaminated by non-displaceable binding-is more appropriate as receptor parameter for group comparisons between patients with Alzheimer's dementia and healthy controls. To account for interindividual variability in the non-displaceable distribution volume (V ND ), V S was calculated using the corpus callosum as part of the white matter as pseudo-reference region, assuming that V T corpus callosum equals V ND in all brain regions, as follows: V S = V T target region À V T corpus callosum. Since the corpus callosum is the region of the brain with lowest V T and mostly devoid of a4b2-nAChRs (Brody et al., 2006) , it was used as pseudo-reference region as published previously by a4b2-nAChR PET using 2-18 F-F-A85380 (Sabri et al., 2008; Meyer et al., 2009; Kendziorra et al., 2011; Okada et al., 2013) . The use of the corpus callosum as pseudo-reference region for between-group comparisons was justified, because V T within the corpus callosum in Alzheimer's dementia and healthy controls was similar and did not differ significantly. To account for morphometric changes that are present in Alzheimer's dementia and elderly healthy controls (Pini et al., 2016) and which may affect the individual volume of interest analysis of the V T data, additional approaches were carried out: the individual volumes of interest used to assess V T were accounted for true grey matter density (GMD) as assessed by voxel-based analysis of MRI. Thus, GMD maskweighted V T values (V T GMDW) were determined. Further, a partial volume effect (PVE) correction on the dynamic PET data, i.e. separately on each acquired time frame, was applied. For that purpose, we used the region-based voxel-wise (RBV) method as previously proposed and implemented (Thomas et al., 2011 (Thomas et al., , 2016 . The PVE-corrected tissue time activity curves from 0-90 min were used for kinetic analysis with a one-tissue compartment model to calculate the PVE-corrected total distribution volume V T PVEC.
MRI procedures and analysis
Subjects received 3 T brain MRI (Magnetom Trio, Siemens Healthcare) mainly to preclude relevant pathological findings not related to Alzheimer's dementia, and to determine the degree of medial temporal lobe atrophy and the extent of white matter lesions based on either the Scheltens or Fazekas Scale (Fazekas et al., 1987; Scheltens et al., 1992) . The imaging protocol included a T 1 -weighted magnetization prepared rapid gradient echo 3D sequence (MPRAGE; repetition time = 2130 ms, echo time = 3.03 ms, inversion time = 1200 ms, matrix 256 Â 256 Â 256, pixel bandwidth 130 Hz) and a transverse T 2 -weighted turbo spin echo sequence. The MRI data were preprocessed using the VBM8 toolbox (http://dbm.neuro.uni-jena.de/vbm/download/) for SPM8 (Wellcome Trust Centre for Neuroimaging, UCL, London, UK) and MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA). The default settings were used while correcting for bias-field inhomogeneity and generating the tissue probability maps for white and grey matter. Nonlinear normalization was carried out using the Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) approach (Ashburner, 2007) . The resulting modulated (corrected for individual brain size) and spatially normalized data were smoothed using an 8 mm FWHM Gaussian kernel.
To denote the modulated and normalized grey matter probability values, the GMD was used. Forebrain analysis of GMD and V T in the basal forebrain was carried out by extracting a binary mask of the basal forebrain cholinergic system (Ch1-3, Ch4) provided by the Anatomy Toolbox in SPM (Eickhoff et al., 2005; Zaborszky et al., 2008) . The averaged GMD and averaged V T inside the mask were calculated. Within the model, we masked the GMD maps by a threshold of 0.1 (absolute thresholding). Values of GMD as assessed by VBM within the hippocampus and basal forebrain in Alzheimer's dementia were compared with healthy controls.
Volume of interest and SPM analysis of PET data
The individual MRI datasets of patients and healthy subjects were spatially reoriented onto a standard brain dataset similar to Talairach space. For volume of interest analysis, cortical, subcortical, white matter and cerebellar regions of interest, except basal forebrain, were manually drawn bilaterally on three consecutive transversal slices (if necessary two or four slices) of the reoriented T 1 -weighted-MPRAGE datasets using PMOD software (PMOD Technologies). The thickness of the MRI slices was transformed to 2.5 mm to enlarge the volume encompassed by the chosen consecutive slices as described previously in detail (Sabri et al., 2015) . The localizations of individually drawn regions of interest for the volume of interest analysis of the PET data are exemplified in the MRI of one study subject (Supplementary material and Supplementary Fig. 1 ). Voxel-based analysis was performed using SPM8. V T maps were spatially normalized onto the individual 3D T 1 MPRAGE MRI and smoothed with 8 mm FWHM on a Gaussian filter.
Statistical analyses
Because this is a first-in-human PET investigation in Alzheimer's dementia using the recently developed radioligand (À)-18 F-flubatine and thus because of the paucity of data and the relatively small number of study cohorts, this study is exploratory in nature. Statistical analyses were performed with IBM SPSS statistic software, version 24. All variables were tested for normal distribution using the KolmogorovSmirnov test. For group comparisons of clinical and cognitive data of Alzheimer's dementia and healthy controls, two-tailed t-tests were performed (significance at P 5 0.05). For group comparisons and correlation analyses regarding the volume of interest-based PET and MRI data, significance was regarded as relevant following correction for multiple testing using the false discovery rate (FDR) correction method (P 5 0.05 corrected ; Benjamini and Hochberg, 1995) . For volume of interest analyses of PET data, the right and left side of the brain were pooled after ruling out significantly relevant right/left asymmetries (paired t-test; significance at P 5 0.05 corrected ). Group comparisons (Alzheimer's dementia versus healthy controls) of PET and MRI data were carried out applying ANCOVA (adjusted for age and sex). For volume of interest analysis, five brain regions with known Alzheimer's dementia pathology were selected a priori, such as the mean cortex (i.e. the frontal, lateral temporal, mesial temporal and parietal cortices), the basal forebrain, the frontal, mesial temporal (hippocampus), and parietal cortices (significance at P 5 0.05 corrected ; Kendziorra et al., 2011; Barthel et al., 2015) . For post hoc volume of interest analysis of-at most-12 additional brain regions, a P 5 0.004 uncorrected (P 5 0.05 corrected ) was accepted as significant. For post hoc, exploratory SPM analysis of V T parametric images, differences were accepted as significant at P 5 0.001 uncorrected , extent threshold k = 5 voxels. Following correction for multiple comparisons, P 5 0.05 [family-wise error (FWE)-, FDR-, or set level-corrected] was considered as highly significant (Friston et al., 1996; Buchert et al., 2004; Meyer et al., 2009) .
To determine whether there were age-, sex-, or educationrelated effects on a4b2-nAChR availability within each cohort (healthy controls or Alzheimer's dementia), volume of interestbased analyses of V T (or V S ) between study cohorts regarding sex were carried out using an unpaired two-tailed t-test (significance at P 5 0.002 uncorrected ; P 5 0.05 corrected ). Correlation analyses between V T (or V S ) and education or age in each study cohort were performed using one-sided Pearson's correlation test (significance at P 5 0.002 uncorrected ; P 5 0.05 corrected ).
Volume of interest-based correlation analyses between PET data in distinct cortical volumes of interest and neuropsychological Z-scores characterizing the five cognitive partial functions (episodic memory, executive function/working memory, attention, language, and visuospatial abilities) were carried out in the Alzheimer's dementia cohort only, using partial correlation analysis (adjusted for education and sex). Significance was accepted at P 5 0.05 corrected . According to review data from the literature, brain regions that are considered to be most relevant for each of the five cognitive domains, were identified as a priori selected volumes of interest. A priori selected volumes of interest were as follows: episodic memory (frontal, mesial temporal, parietal cortices and basal forebrain), executive function/working memory (frontal and parietal cortices), language (frontal and temporal cortices), attention (frontal and parietal cortices), and visuospatial function (parietal and occipital cortices; Cabeza and Nyberg, 2000; Foxe et al., 2016) . To explore correlations between episodic memory and PET data within subregions of the mesial temporal cortex, post hoc volume of interest-based correlation analysis between episodic memory and a4b2-nAChR availability within hippocampus and amygdala was carried out.
Post hoc, exploratory, voxel-based correlation analyses between parametric images of V T and the five cognitive domains (Z-scores) in Alzheimer's dementia were performed, and an exploratory P 5 0.001 uncorrected , extent threshold of k = 5 voxels was considered significant. Clusters surviving FWE, FDR, or set-level-correction at P 5 0.05 were accepted as highly significant (Friston et al., 1996; Buchert et al., 2004; Meyer et al., 2009) .
Results

Study subjects
Patients with Alzheimer's dementia and healthy controls did not differ significantly from each other in education (13.1 AE 2.2 versus 13.8 AE 1.5 years; P = 0.378), age (75.1 AE 6.2 versus 71.3 AE 4.7 years; P = 0.071), and sex distribution (Alzheimer's dementia: four males/10 females, healthy controls: eight males/seven females; P = 0.264). MMSE was significantly lower in Alzheimer's dementia compared with healthy controls (24.0 AE 2.6 versus 28.4 AE 0.9, P 5 0.001). Patients with Alzheimer's dementia, compared with healthy controls, had significantly higher GDS scores (7.4 AE 3.6 versus 3.3 AE 2.2, P 5 0.001) indicating mild depressive symptoms. In Alzheimer's dementia, compared with healthy controls, Scheltens scores were significantly higher (1.4 AE 1.0 versus 0.7 AE 0.5, P = 0.025) implying atrophic, hippocampal changes. In Alzheimer's dementia, compared with healthy controls, in both cohorts, Fazekas scores were mildly increased, indicating mild white matter hyperintensities and thus mild small vessel disease. In Alzheimer's dementia, compared with healthy controls, there was a trend for higher Fazekas scores, without reaching significance (deep white matter hyperintensities: 1.3 AE 0.7 versus 0.8 AE 0.6, P = 0.053; periventricular white matter hyperintensities: 1.3 AE 0.8 versus 0.8 AE 0.7, P = 0.074) (Supplementary material and Supplementary Table 1 ). Compared with healthy controls, patients with Alzheimer's dementia showed significantly lower Z-scores in most cognitive tests, derived from the cognitive test battery, resulting in significantly lower Z-scores in four out of the five cognitive domains. Z-scores were mostly reduced in Alzheimer's dementia regarding visuospatial function and episodic memory followed by language and executive function/working memory (P 5 0.001). The Z-score of attention did not significantly differ between Alzheimer's dementia and healthy controls (P = 0.161) ( Table 1 and  Supplementary Table 2 ).
Image data of neurodegeneration
Kinetic modelling of the PET data indicated in Alzheimer's dementia, compared with healthy controls, significantly lower K 1 values within the composite volume of interest of the fronto-temporo-parietal cortices (0.31 AE 0.04 versus 0.35 AE 0.04; À11%; P = 0.006; P 5 0.05 corrected ). VBM analysis revealed that in Alzheimer's dementia, compared with healthy controls, there was significantly lower greymatter density in the hippocampus (right/left side pooled; 0.54 AE 0.11 versus 0.66 AE 0.06; À18%; P 5 0.001; P 5 0.05 corrected ) and basal forebrain (0.29 AE 0.05 versus 0.36 AE 0.03; À19%; P 5 0.001; P 5 0.05 corrected ).
Asymmetry of a4b2-nAChR availability within the brain
Following correction for multiple comparisons, no significant asymmetric differences within the brain of Alzheimer's dementia or healthy controls for any quantitative PET parameters of a4b2-nAChR availability were found.
Effect of education, sex and age on a4b2-nAChR availability Following correction for multiple comparisons, in both cohorts there were no significant correlations between education or age and V T (or V S ) within any of the 18 brain regions that were studied. Furthermore, no sex-related differences of V T (or V S ) were found.
a4b2-nAChR availability in Alzheimer's dementia and healthy controls
Parametric images of the V T exemplify typical regional a4b2-nAChR availability within the brain of one representative patient with Alzheimer's dementia and one healthy control subject, i.e. high within the thalamus, moderate within the striatum, brainstem, cerebellum and white matter centrum semiovale, low within the neocortex and limbic regions and very low within the corpus callosum. Compared to the healthy control subject, lower cortical, subcortical and cerebellar V T in the patient with Alzheimer's dementia can be visualized (Fig. 1) . ANCOVA of volume of interest data revealed that in Alzheimer's dementia, there was significantly lower V T in four of the five a priori selected brain regions reaching significance within the composite volume of interest including fronto-temporo-parietal cortices (mean cortex; À5%; P = 0.015; P 5 0.05 corrected ), within the frontal cortex (À5%; P = 0.020; P 5 0.05 corrected ), hippocampus as part of the mesial temporal cortex (À10%; P = 0.001; P 5 0.05 corrected ), and basal forebrain (À10%; P = 0.003; P 5 0.05 corrected ; Table 2 ). For exploratory post hoc analyses, in Alzheimer's dementia, there was significantly lower V T within the right anterior cingulate cortex (À3%; P = 0.028; P 5 0.05 uncorrected ), thalamus (À9%; P = 0.011; P 5 0.05 uncorrected ), pons/midbrain (À7%; P = 0.027; P 5 0.05 uncorrected ), cerebellar cortex (À6%; P = 0.031; P 5 0.05 uncorrected ), and white matter centrum semiovale (À1%; P = 0.021; P 5 0.05 uncorrected ), although none of those post hoc comparisons remained significant after correction for multiple comparisons.
Volume of interest analysis of V S data revealed very similar findings as obtained by analysis of V T . In Alzheimer's dementia, there was widespread lower V S reaching significance within four of the five a priori selected brain regions such as the mean cortex (À14%, P = 0.009, P 5 0.05 corrected ), frontal cortex (À13%, P = 0.016, P 5 0.05 corrected ), hippocampus as part of the mesial temporal cortex (À23%, P = 0.002, P 5 0.05 corrected ), and basal forebrain (À34%, P = 0.019, P 5 0.05 corrected ). For post hoc selected brain regions, V S was significantly lower within the anterior cingulate cortex (À8%, P = 0.039; P 5 0.05 uncorrected ), within the thalamus (À12%, P = 0.021; P 5 0.05 uncorrected ) and the centrum semiovale in the white matter (À2%, P = 0.030; P 5 0.05 uncorrected ), although those post hoc findings for group comparisons did not remain significant after correction for multiple comparisons (Supplementary material and  Supplementary Table 3) .
Compared with healthy controls, in Alzheimer's dementia, there was significantly lower V T GMDW and V T PVEC within similar a priori selected cortical brain regions, as found by between-group comparisons for V T and V S measures. In contrast to V T (and V S ) measures, however, for V T GMDW and V T PVEC, following correction for multiple comparisons, significance in those a priori regions was reached only within the hippocampus and basal forebrain. In Alzheimer's dementia, compared with healthy controls, per cent reductions of V T GMDW were the lowest (Supplementary material, Supplementary Tables 4  and 5 ).
The explorative post hoc SPM analysis supported the findings from the volume of interest analyses, although significant clusters within the cortical brain regions typically affected by Alzheimer's dementia pathology were small. In Alzheimer's dementia, there were clusters with significantly lower V T in the neocortex especially within the a priori defined brain regions such as the fronto-temporo-parietal cortices, the right hippocampus, and also within the cingulate cortex (P 5 0.001 uncorrected ; extent threshold k = 5 voxels; P 5 0.05 set-level corrected ; Fig. 2 and Table 3 ).
Relationship between a4b2-nAChR availability and cognition in Alzheimer's dementia
In patients with Alzheimer's dementia, the volume of interestbased correlation analyses revealed that there were significant positive associations between episodic memory and V T within a priori defined brain regions such as the frontal (r = 0.78; P = 0.004), mesial temporal (r = 0.71; P = 0.01) and parietal cortices (r = 0.67; P = 0.02) (all P 5 0.05 corrected ; Table 4 ). There was no significant relationship between memory and V T within the basal forebrain (r = 0.40; P = 0.13). Executive function/working memory and V T showed significant positive associations within the frontal (r = 0.57; P = 0.04) and parietal cortices (r = 0.81; P = 0.002) (all P 5 0.05 corrected ; Table  4 ). There were no significant correlations between attention and V T within the frontal and parietal cortices, between language and V T within the frontal and temporal cortices, and between visuospatial function and V T within the parietal and occipital cortices (Table 4) . Furthermore, exploratory, voxel-based correlation analyses identified significant positive correlations between memory dysfunction (Z-scores) and parametric images of reduced V T Figure 1 Parametric images of a4b2-nAChR availability (V T ) in a patient with Alzheimer's dementia and a healthy control subject. Parametric images of the V T co-registered to individual MRI (transaxial views) exemplify the pattern of regionally distinct a4b2-nAChR availability in one representative patient with Alzheimer's dementia (top; male, aged 75 years, MMSE = 25, CDR = 1) and one healthy control subject (bottom; female, aged 71 years, MMSE = 28, CDR = 0). In the Alzheimer's dementia patient, compared with the healthy control subject, widespread decrease of a4b2-nAChR availability (V T ) within the cortex and thalamus was observed. As indicated by the pseudo-coloured bar, V T values range from low (blue) to high (red). ANCOVA for the comparison of V T between Alzheimer's dementia and healthy controls (adjusted for age and sex), within five a priori defined cortical brain regions, such as mean cortex, frontal, mesial temporal (hippocampus), parietal cortices, and basal forebrain (in bold); significance at P 5 0.05 corrected (FDR correction according to Benjamini-Hochberg; in bold). Furthermore, exploratory post hoc analysis for 12 additional brain regions, significance at P 5 0.004 uncorrected (P 5 0.05 corrected ; FDR correction). AD = Alzheimer's dementia; HC = healthy controls.
in Alzheimer's dementia, especially within the left basal forebrain and left inferior frontal cortex (cluster level: P = 0.003 uncorrected ; P 5 0.05 FWE-corrected ), and furthermore, although not significant following correction for multiple comparisons, between the inferior temporal cortex, bilaterally, including the left parahippocampal gyrus (Fig. 3A and Table 5 ). There were significant, positive correlations between impaired executive function/working memory and lower V T within the left inferior temporal, right superior temporal and right parietal cortices in Alzheimer's dementia (Fig. 3B and Figure 2 Reduced a4b2-nAChR availability (V T ) in Alzheimer's dementia compared with healthy controls using SPM analysis.
Exploratory post hoc SPM analysis for the comparison of V T parametric images in Alzheimer's dementia and healthy controls. Coloured clusters projected into transaxial slices of a standard MRI brain indicate significantly lower V T in patients with Alzheimer's dementia compared with healthy controls, especially within the fronto-temporo-parieto cortices, and limbic regions (parahippocampus, posterior cingulate cortex). ANCOVA for group comparisons (adjusted for age and sex). Significance at P 5 0.001 uncorrected ; k = 5 voxels; P 5 0.05 set-level corrected .
Table 5) (P 5 0.001 uncorrected ). There were significant, positive associations between impairment of attention and reduced V T within the right frontal white matter, left thalamus, and left putamen in Alzheimer's dementia ( Fig. 3C and Table 5 ) (P 5 0.001 uncorrected ). Significant, positive associations between language and V T within the right cerebellum (crus 1 and 2) in Alzheimer's dementia were found (Table 5 , P 5 0.001 uncorrected ). No significant positive correlations between V T and visuospatial function were identified. There were no significant, negative correlations between any cognitive domains and V T . Post hoc volume of interest-based correlation analysis between episodic memory and PET data within subregions of the mesial temporal cortex showed a trend for a positive correlation within the hippocampus and a significant, positive correlation within the amygdala (Supplementary material). As compared to V T , major findings for those correlations between cognition and additional PET Bold coefficients represent significant correlations after controlling for multiple testing according to Benjamini-Hochberg (P 5 0.05 corrected ). df = degrees of freedom; n.a. = not applicable; r = correlation coefficient; WM = working memory.
parameters were similar, although the significance levels were lower (Supplementary material).
Discussion
Using novel (À)-
18
F-flubatine and PET, the availability of a4b2-nAChRs in the brain of non-smoking, cholinergic drug-naïve patients with mild Alzheimer's dementia was quantitatively investigated and compared with healthy controls. This was accomplished to answer the question whether there is lower a4b2-nAChR availability early in the course of Alzheimer's dementia and whether this a4b2-nAChR state is related to cognitive decline (Sabri et al., 2008; Kendziorra et al., 2011; Okada et al., 2013) . PET analyses in Alzheimer's dementia reveal that there is a reduction of a4b2-nAChR availability in a priori defined multiple cortical brain regions as measured in absolute (V T ) and relative quantitative parameters (V S ). Regardless of the method used to quantify the a4b2-nAChR availability by kinetic modelling of PET data, brain regions typically affected by Alzheimer's dementia, such as the basal forebrain, hippocampus, and fronto-temporal cortices, demonstrate a deficiency. Regarding regional preferences of this deficiency, in Alzheimer's dementia, the a4b2-nAChR availability is mostly reduced in the hippocampus and basal forebrain, i.e. À10% and À10% in V T and À23% and À34%, respectively, in V S . As V S is proportional to the receptor density, the reduction of V S in Alzheimer's dementia is a direct measure of the reduction of the a4b2-nAChR density. The lower per cent reduction of V T (as compared to V S ) reflects the additional non-displaceable distribution volume V ND (i.e. V ND = V T À V S ), which is, as assessed by V T corpus callosum, not different in Alzheimer's dementia and healthy controls (Innis et al., 2007) . As exploratory post hoc volume of interest analysis suggests, though not significant following correction for multiple testing, there may be also lower a4b2-nAChR availability within additional brain regions such as the pons, thalamus, and cerebellar cortex in mild Alzheimer's dementia. If these adjunct findings are verified in future PET studies, in mild Alzheimer's dementia, diminutions of cholinergic a4b2-nAChRs may not be restricted to the basal forebrain-cortical and septohippocampal cholinergic projections, but may be present also within the pontinethalamic-cortical projection system, possibly representing dysfunction of non-cholinergic, e.g. noradrenergic systems, known to express a4b2-nAChRs (Dani and Bertrand, 2007; Theofilas et al., 2017) .
Our results strongly support and extend earlier PET/ SPECT findings using first-generation, a4b2-nAChR-specific radioligands, such as 2- Those PET/SPECT studies detected lower a4b2-nAChR availability in mild-to-moderate Alzheimer's dementia only by relative quantitative measures (O'Brien et al., 2007; Sabri et al., 2008; Kendziorra et al., 2011; Okada et al., 2013) . However, those results were not supported by other PET/ SPECT imaging studies using the absolute quantitative Figure 3 Cognitive correlates of lower a4b2-nAChR availability (V T ) in Alzheimer's dementia as assessed by SPM analysis. Exploratory, linear correlation analyses using SPM identify significant positive correlations between parametric images of V T and impairment of various cognitive domains (Z-scores) in Alzheimer's dementia as projected into a standard MRI brain and indicated by coloured clusters (significance at T 4 3.93; P 5 0.001 uncorrected ; k = 5 voxels). Memory dysfunction is positively correlated with V T especially within the left basal forebrain and inferior frontal cortex (cluster-level: P = 0.003 uncorrected ; P 5 0.05 FWE-corrected ) and inferior temporal cortex and parahippocampus (A). There is a positive relationship between altered executive function/working memory and V T within the left inferior temporal, right superior temporal and right parietal cortices (B). Impairment of attention is positively associated with lower V T within the right frontal white matter, left thalamus, and left putamen (C). No significant negative correlations were found. measure V T as outcome measure to assess a4b2-nAChR availability in mild Alzheimer's dementia, leading to an ongoing controversy (Ellis et al., 2008; Mitsis et al., 2009b) . Conflicting results by prior PET/SPECT studies may not only be due to methodological differences how to quantify the a4b2-nAChR availability, but also due to clinical data variability, such as heterogeneity of dementia severity, presence of genetic risk factors, and differences in the age of onset of the disease.
In the present (À)-
F-flubatine PET study, significantly lower a4b2-nAChR availability in Alzheimer's dementia was found, which ranges from À5 to À10% for V T and À13 to À34% for V S , differences that are smaller than expected from respective post-mortem studies (Rinne et al., 1991; Perry et al., 1995) . These findings are less surprising since most of the Alzheimer's dementia patients investigated in our PET study have only mild dementia and 13 of 14 (93%) have the most common form of late onsettype Alzheimer's dementia. Moreover, the post-mortem studies used 3 H-nicotine, a radioligand that does not bind selectively to a4b2-nAChRs, as suggested by the presence of high-and low-affinity binding sites (Perry et al., 1989) . Of interest and similar to our findings regarding a4b2-nAChRs, modest diminutions of brain acetylcholinesterase, vesicular acetylcholine transporters and glucose metabolism using PET/SPECT in (mild) late-onset Alzheimer's dementia, were reported, mainly present within the temporal cortex (Kuhl et al., 1996; Bohnen et al., 2003; Kim et al., 2005) . These findings in late-onset Alzheimer's dementia were in contrast to more pronounced and widespread cortical defects in early-onset Alzheimer's dementia (Kuhl et al., 1996; Kim et al., 2005) . The relatively small, mean between-group differences of a4b2-nAChR availability might also be due to variance in both cohorts, reflecting normal, interindividual differences, ageing-related effects, and/or compensatory changes in early Alzheimer's dementia (Ellis et al., 2008; Kantarci et al., 2010) . Of note, in mild Alzheimer's dementia, decrease of a4b2-nAChR availability is most pronounced in the mesial temporal cortex and basal forebrain where tau aggregations start (Yin, et al., 2016) . In this regard, recent experimental studies and a combined amyloid-b and a4b2-nAChR PET investigation in Alzheimer's dementia determined direct relationships between a4b2-nAChRs and tau or amyloid-b aggregations, hallmarks of Alzheimer's dementia pathology (Okada et al., 2013; Ballinger et al., 2016; Yin et al., 2016) . Future clinical PET association studies using radioligands to quantitatively assess tau and/or amyloid-b aggregations and a4b2-nAChR availability in Alzheimer's dementia will highly improve the understanding of a4b2-nAChR pathophysiology, and help to develop novel drug therapies (Okada et al., 2013; Lombardo and Maskos, 2015; Kamkwalala and Newhouse, 2017) . As compared to 18 F-FDG, which is currently used as clinical symptomatic disease PET biomarker of Alzheimer's dementia, and compared to tau PET tracers, which are currently tested in a similar regard, we see the potential advantage of (À)-18 F-flubatine PET by delivering specific information on the integrity of the cholinergic system, potentially simplifying 'go' or 'no-go' decisions on specific cholinergic treatment (Richter et al., 2018) . To investigate this feature, however, additional comparative PET tracer studies connected with clinical outcome readouts after treatment will be required.
Correlation analyses reveal that, in patients with Alzheimer's dementia, there is a strong relationship between impaired episodic memory and reduced a4b2-nAChR availability, especially within the fronto-temporo-parietal cortices and basal forebrain, such brain regions in which a4b2-nAChR diminutions are most pronounced in Alzheimer's dementia. The regional pattern of these associations, especially within the fronto-temporo-parietal cortices and basal forebrain, is in line with previous investigations (Cabeza and Nyberg, 2000) . Thus, our PET findings strongly support and extend the cholinergic a4b2-nAChRs hypothesis for patients with mild Alzheimer's dementia, which has been challenged and revisited previously (Ellis et al., 2008; Sabri et al., 2008; Mitsis et al., 2009b; Okada et al., 2013; Ballinger et al., 2016) . To our knowledge, this is the first report to identify in vivo associations between a4b2-nAChR availability, especially within basal forebrain, fronto-temporo-parietal cortices, and parahippocampus and episodic memory in patients with mild Alzheimer's dementia.
There is a strong association (significant following correction for multiple comparisons) between altered executive function/working memory and lower a4b2-nAChR availability, within the a priori defined fronto-parietal cortices in Alzheimer's dementia. Further, results of post hoc exploratory SPM analysis suggest, however not significant following testing for multiple comparisons, that there might be an additional relationship between executive function/ working memory and lower a4b2-nAChR availability with the temporal cortex. Findings of two a4b2-nAChR PET/SPECT studies in mild-to-moderate Alzheimer's dementia using 2-18 F-F-A85380 or 5-123 I-I-A85380 demonstrated associations between impaired executive function and lower a4b2-nAChR availability, especially within the frontal cortex, supporting our results in part (Colloby et al., 2010; Okada et al., 2013) . Thus, findings suggest that the a priori defined network comprised of the fronto-parietal cortices, being assumed to be mainly associated with executive function/working memory, might be extended to the temporal cortex if confirmed by future PET investigations (Levin et al., 2006; Graef et al., 2011; Ballinger et al., 2016; Bettcher et al., 2016) .
There is no significant correlation between impaired attention and decreased a4b2-nAChR availability within the a priori selected brain regions, such as the frontal and parietal cortices using volume of interest analysis in Alzheimer's dementia. Exploratory SPM analysis suggests that, although not significant following correction for multiple comparisons, there may be a relationship between reduced a4b2-nAChR availability in frontal white matter and subcortical brain regions such as the thalamus and putamen and dysfunction of attention. The PET findings support the view that fronto-thalamic-striatal a4b2-nAChRs contribute to the functional cholinergic network of attention (Sarter et al., 2001; Howe et al., 2010) .
Exploratory SPM analysis suggests that there might be a relationship between dysfunction of language and lower a4b2-nAChR availability within the right cerebellar cortex (crus 1 and 2) in Alzheimer's dementia. Although not significant following correction for multiple comparisons, this finding is in agreement with results of a meta-analysis investigating the functional topography of the cerebellum and identifying lobule VI and VII and crus 1 within the right posterior cerebellum to be associated with language (Stoodley and Schmahmann, 2009; Buckner, 2013) . There is no significant relationship between visuospatial dysfunction and regional a4b2-nAChR availability in Alzheimer's dementia, which is in line with findings of prior a4b2-nAChR PET/SPECT studies (Meyer et al., 2014) .
In both study cohorts, there were no associations between education or age and a4b2-nAChR availability, and no sex-related differences of the a4b2-nAChR availability. Although previously reported using a4b2-nAChR PET/SPECT, the lack of a relationship between age or sex and a4b2-nAChR binding in this PET study may be explained by the relatively small size of the study cohorts, the small age range in both cohorts, and by the fact that in Alzheimer's dementia, a4b2-nAChR availability is influenced by distinct neuropathology (Meyer et al., 2009; Mitsis et al., 2009a) .
There are the following limitations. First, the clinical diagnostic criteria of Alzheimer's dementia (NINCDS-ADRDA), as used in this study, may lack accuracy. Enrichment of the Alzheimer's dementia group by biomarkers of amyloid pathology, like amyloid-b PET, was not approved by the regulatory authorities. Thus, our Alzheimer's dementia cohort might contain patients suffering from other forms of dementia. To reduce this risk, we investigated K 1 PET data within fronto-temporo-parietal cortices as calculated by pharmacokinetic modelling from the (À)- 18 F-flubatine PET data. K 1 of (À)-18 F-flubatine is closely correlated to cerebral blood flow and may therefore serve as an indirect measure of the degree of neurodegeneration. Further, VBM analyses of grey matter density within the basal forebrain and hippocampus were carried out in Alzheimer's dementia and healthy controls. In Alzheimer's dementia, the K 1 PET and VBM analyses concordantly showed signs of neurodegeneration in brain regions typically affected in Alzheimer's dementia, by that supporting the clinical diagnoses. Second, although we investigated only mild Alzheimer's dementia, atrophyrelated partial volume effects affecting a4b2-nAChR PET data analysis may be present and should be taken into account. To minimize atrophy-related effects, irregular brain tissue-containing volumes of interest were defined based on the individual MRI after MRI/PET co-registration. Additionally, grey matter density mask-weighted V T values and partial volume effect corrected V T values were calculated for each subject. The pattern of regionally lower V T GMDW, V T PVEC and V T in Alzheimer's dementia compared with healthy controls, was similar. Furthermore, for those PET parameters very close correlations between V T , V T GMDW, and V T PVEC and specific cognitive partial functions were found in Alzheimer's dementia. Therefore, a major effect of brain atrophy on these PET findings can be ruled out.
To summarize, in mild Alzheimer's dementia, there is a widespread reduction of cholinergic a4b2-nAChR availability especially within the hippocampus, fronto-temporal cortices, and basal forebrain, most pronounced within the mesial temporal cortex (hippocampus) and basal forebrain. Further, in Alzheimer's dementia, there is a relationship between networks of decreased a4b2-nAChR availability, especially within fronto-temporo-parietal cortices and basal forebrain and impairment of episodic memory, and within fronto-parietal cortices and impairment of executive function/working memory. This shows the potential of (À)-18 F-flubatine as PET biomarker of cholinergic a4b2-nAChR vulnerability and specific cognitive decline. Thus, (À)-18 F-flubatine might become a biomarker of progression of a4b2-nAChR neurodegeneration in Alzheimer's dementia. This hypothesis, however, needs to be proved by prospective, longitudinal PET investigations.
